Radius Health ("Radius" or "the Company"), a specialty biopharmaceutical company dedicated to bone health and related therapeutic areas, including through its lead product TYMLOS(R) (abaloparatide) ...
Transaction follows three years of accelerated growth and successful operations under B‑FLEXION and Patient Square's ownership. BOSTON, Jan. 12, 2026 /PRNewswire/ -- Radius Health ("Radius" or "the ...
Radius' lead product, TYMLOS® (abaloparatide) injection, a parathyroid hormone related peptide, is approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women and men ...
Dec. 30, 2025 – updated Jan. 5, 2026 – Injectable GLP-1 drugs have transformed obesity treatment – and now they're going oral. "It's good to have more options for patients with obesity," said Melanie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results